New insights into the management of hand-foot syndrome have been provided by clinical trials evaluating the novel oral fluoropyrimidine capecitabine (Xeloda). Capecitabine was rationally designed to generate fluorouracil (5-FU) preferentially in tumor tissue[4] and offers sustained 5-FU delivery to tumors, thus mimicking continuous-infusion 5-FU. Like continuous-infusion 5-FU, one of the side effects of treatment with capecitabine is hand-foot syndrome. - See more at: http://www.cancernetwork.com/review-article/coming-grips-hand-foot-syndrome#sthash.9FDSBOmi.dpuf